The global juvenile idiopathic arthritis diagnostic market size is worth around USD 6,320 million in 2024 and is anticipated to reach around USD 9,445 million by 2034, growing at a CAGR of 4.1% from 2024 to 2034.
Due to the growing concerns about the health of children who do not have access to health care, there is an increasing emphasis on children’s well-being, which further contributes to market expansion. Juvenile idiopathic arthritis (JIA) is the most common type of arthritis in children under the age of 16. With the increasing prevalence of JIA worldwide, there is a high demand for reliable diagnostic solutions. Moreover, the increasing awareness about the importance of early diagnosis boosts the market, as early diagnosis of JIA prevents long-term joint damage and disabilities. Technological advancements in diagnostic technologies led to the development of sensitive biomarkers and advanced imaging solutions, which made early diagnosis possible.
While blood tests play an important role in detecting certain biomarkers linked to JIA, imaging technologies are gaining immense traction due to their accuracy in identifying inflammation and damage to the joint. The increasing government initiatives to advance healthcare infrastructure and make healthcare technologies easily accessible in rural areas are expected to create immense opportunities in the juvenile idiopathic arthritis diagnostics market.
Published by Ajit Bansod
